x
 
 
 
 

About Us

Leadership Team

photo team

Eric I. Richman

Chief Executive Officer

Eric I. Richman has served as chief executive officer and as a member of the board of directors since July 2020. Mr. Richman has over 25 years of experience in the biotechnology and pharmaceutical industries as an investor and in operational roles. Mr. Richman currently serves as a director of Neubase Therapeutics and NovelStem International Corp., co-founder and chairman of InFuse Holdings and chairman of the board of LabConnect. He developed his career as a venture partner at Brace Pharma Capital, a life science venture capital firm, and as an advisor to Broad Oak Capital, a life science private equity firm. Mr. Richman has also previously served as chief executive officer of Tyrogenex and PharmAthene, subsequently acquired by Altimmune. Prior to PharmAthene, Mr. Richman held various commercial and strategic positions at MedImmune over a 12-year period from its inception. He has previously served as a director of Adma Biologics, Zyversa Therapeutics, and LEV Pharma, which was acquired by Viropharma, among others private and public companies. Mr. Richman received a B.S. in Biomedical Science from the Sophie Davis School of Biomedical Education (CUNY Medical School) and an MBA from the American Graduate School of International Management.

 

 
 
 

Research and Development Collaborations

lilly 

 

Grants

Grants Grants Grants Grants

 

Patient Associations

Patient Associations Patient Associations Patient Associations Patient Associations

Centers of Research, Translational Science & Clinical Excellence

Centers of Research Centers of Research Centers of Research Centers of Research Centers of Research Centers of Research
Centers of Research Centers of Research Centers of Research Centers of Research Centers of Research Centers of Research
 

Interested in working with a dynamic team of research,
medical and business professionals? 

View Job opportunities